ASP8273
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Subjects With NSCLC With an EGFR Activating Mutation
Conditions
Subjects With NSCLC With an EGFR Activating Mutation
Trial Timeline
Feb 28, 2017 → Feb 28, 2017
NCT ID
NCT03042013About ASP8273
ASP8273 is a phase 2 stage product being developed by Astellas Pharma for Subjects With NSCLC With an EGFR Activating Mutation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03042013. Target conditions include Subjects With NSCLC With an EGFR Activating Mutation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03042013 | Phase 2 | Withdrawn |
| NCT02192697 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Subjects With NSCLC With an EGFR Activating Mutation